Poplar Therapeutics vs Insilico Medicine
Side-by-side comparison of AI visibility scores, market position, and capabilities
Raised $95M total ($50M Series A Jan 2026 + $45M extension Mar 2026) from SR One, Vida, RA Capital, Janus Henderson. Triple-action anti-IgE mechanism. Phase 1 data expected H2 2026 for PHB-050.
About
Poplar Therapeutics (formerly Phylaxis Bioscience) raised $95 million in less than 60 days — $50 million in Series A financing in January 2026 from SR One, Vida Ventures, RA Capital, and Janus Henderson, extended by $45 million in March 2026 — reflecting exceptional investor conviction in its PHB-050 anti-IgE program. PHB-050 uses a triple-action anti-IgE mechanism designed to exceed the performance of existing anti-IgE drugs: simultaneously blocking mast cell IgE binding, reducing circulating free IgE, and inhibiting IgE production by B cells. Phase 1 data is expected in the second half of 2026.
Insilico Medicine (HKEX: 3696) raised $293M, posted $56.2M revenue in 2025, and inked a $2.75B Eli Lilly deal in 2026 using generative AI to discover drug targets in cancer and CNS.
About
Insilico Medicine is a clinical-stage biotechnology company founded in 2014 that leverages generative AI for drug discovery and development. Headquartered in Boston with offices in Hong Kong and New York, the company has built AI platforms utilizing deep generative models, reinforcement learning, and transformers to discover novel drug targets and generate molecular structures with desired properties. Its pipeline spans cancer, fibrosis, CNS diseases, infectious diseases, autoimmune conditions, and aging-related diseases.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.